Elan (ELN) looks to add to recent gains on rumors of a possible takeover bid from Johnson & Johnson (JNJ), as the stock hit 52-week highs yesterday despite a bearish safety update on its Tysabri treatment for multiple sclerosis. JNJ already holds an 18% stake in ELN and pays out 49.9% of its income on its Alzheimer's drug to ELN.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/